By Dean Seal ( April 13, 2018, 5:52 PM EDT) -- A proposed class of Valeant Pharmaceuticals shareholders told a New Jersey federal judge Thursday that all of the claims against the company, its executives and several banks over a price-gouging scheme that cost shareholders $80 billion were adequately pled, contrary to a volley of partial dismissal bids pushed by the defendants....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.